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Worsening Depressive Symptoms
Are Associated With Adverse Clinical
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Objectives The purpose of this study was to assess the impact of changes in symptoms of depression over a 1-year period
on subsequent clinical outcomes in heart failure (HF) patients.
Background Emerging evidence shows that clinical depression, which is prevalent among patients with HF, is associated with a poor
prognosis. However, it is uncertain how changes in depression symptoms over timemay relate to clinical outcomes.
Methods One-hundred forty-seven HF outpatients with ejection fraction of less than 40% were assessed for depressive
symptoms using the Beck Depression Inventory (BDI) at baseline and again 1 year later. Cox proportional haz-
ards regression analyses, controlling for established risk factors, were used to evaluate how changes in depres-
sive symptoms were related to a combined primary end point of death or cardiovascular hospitalization over a
median follow-up period of 5 years (with a range of 4 to 7 years and no losses to follow-up).
Results The 1-year change in symptoms of depression, as indicated by higher BDI scores over a 1-year interval (1-point
BDI change hazard ratio [HR]: 1.07, 95% confidence interval [CI]: 1.02 to 1.12, p  0.007), was associated with
death or cardiovascular hospitalization after controlling for baseline depression (baseline BDI HR: 1.1, 95% CI:
1.06 to 1.14, p  0.001) and established risk factors, including HF cause, age, ejection fraction, plasma
N-terminal pro–B-type natriuretic peptide level, and prior hospitalizations.
Conclusions Worsening symptoms of depression are associated with a poorer prognosis in HF patients. Routine assessment
of symptoms of depression in HF patients may help to guide appropriate medical management of these patients
who are at increased risk for adverse clinical outcomes. (J Am Coll Cardiol 2011;57:418–23) © 2011 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.09.031C
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rith more than 5 million Americans living with heart
ailure (HF), and another 670,000 new cases being
iagnosed each year, HF is the most costly diagnosis in
he Medicare population and is the most common cause
or hospitalization in patients older than 65 years (1).
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ccepted September 13, 2010.linical depression also is common in HF, with preva-
ence estimates ranging from 24% to 42% (2). Studies
rom multiple investigative teams, including our own,
ave found that, independent of HF disease severity,
epressive symptoms are associated with adverse clinical
utcomes for HF patients (3– 8). Moreover, depressive
ymptoms that increase over time also have been associ-
ted with worse outcomes in patients with myocardial
nfarction (MI) (9 –11). Although changes in depressive
See page 424
ymptoms have been assessed previously in HF patients
12,13), their relationship to HF clinical outcomes has
ot been evaluated. The present study extends our prior
eport (3) by evaluating the unique contribution of
hanges in depressive symptoms at 1 year of follow-up in
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January 25, 2011:418–23 Depression and Heart Failurehe context of established risk factors, including baseline
epressive symptoms and established HF disease severity
iomarkers, on subsequent clinical outcomes defined by hos-
italization or death across an overall median follow-up period
f 5 years.
ethods
his was a prospective, observational study of a nonhospi-
alized cohort of HF patients, recruited from outpatient HF
linics in central North Carolina. We performed medical
nd psychosocial assessments at baseline and at the 1-year
ollow-up to evaluate their association with events, includ-
ng mortality and hospitalizations over a median follow-up
eriod of 5 years from baseline assessments (median of 4
ears from the 1-year follow-up assessments with range of 3
o 6 years and no losses to follow-up).
articipants. The study sample comprised 147 patients
ecruited from the Heart Failure Programs at Duke Uni-
ersity Medical Center and the University of North Caro-
ina Health Care at Chapel Hill from January 2000 through
ecember 2002. This sample represents a subset of the 204
articipants whom we initially recruited (3); 27 patients died
ithin the first year and 30 were alive but were unavailable
o complete the depression assessment at the 1-year follow-
p. Inclusion criteria were: left ventricular ejection fraction
LVEF) of 40% or less, documented within the last year by
ngiography, radionuclide ventriculography, or echocardi-
graphy; and New York Heart Association functional
lasses I to IV for at least 3 months in duration. Exclusion
riteria were: pacemaker dependence; uncontrolled hyper-
ension; MI, percutaneous coronary intervention, or coro-
ary artery bypass graft within the last 3 months; and a
atient’s first visit to the heart failure clinic. Pacemaker
ependence, fewer than 3 months after MI, percutaneous
oronary intervention, and coronary artery bypass graft were
xcluded because the study also was designed to evaluate
utonomic nervous system regulation. The study was ap-
roved by the Institutional Review Board at Duke Univer-
ity Medical Center, where all assessments were performed.
ritten informed consent was obtained from all partici-
ants before their participation.
aseline assessments. MEDICAL. Clinical information and
edical history were obtained from medical records. Med-
cations were documented as medications being taken at the
ime of baseline assessments, including both cardiac and
sychotropic medications.
-TERMINAL PRO–B-TYPE NATRIURETIC PEPTIDE (NT-PROBNP).
fter 20 min of seated relaxation, blood was collected
rom an antecubital vein in a 5-ml phlebotomy tube
ontaining ethylenediaminetetraacetic acid. Samples were
laced on ice and were cold-centrifuged at 1,000  g for 10
in. The resulting plasma was pipetted into plastic vials and
rozen and maintained at 80°C until assay. On the day of
T-proBNP analysis, samples were thawed in a room tem-erature water bath and then mixed thoroughly. NT-proBNP teasurements were performed
ithin 4 hours of thawing using
n electrochemiluminescence
mmunoassay in accordance with
he manufacturer’s instructions
Elecsys proBNP, Roche Diag-
ostics Corporation, Indianapo-
is, Indiana). The analytical mea-
urement range for the assay is 5
o 35,000 pg/ml, and typical day-
o-day imprecision has a coeffi-
ient of variation of less than 5%.
EFT VENTRICULAR EJECTION
RACTION (LVEF). LVEF was
etermined by 2-dimensional
chocardiography. Apical 4- and
-chamber images of the heart
ere acquired by a single sonog-
apher using an Acuson (Mountain View, California) ultra-
ound machine and were stored as digital loops. The
ndocardial borders of the left ventricle in the 2 views were
raced by a single experienced echocardiography specialist
A.L.H.) using customized off-line software (Access Point
000, Freeland Systems, LLC, Westfield, Indiana), and
entricular volumes and LVEF were computed using the
iapical Simpson’s rule.
EPRESSION. The Beck Depression Inventory (BDI) is a
1-item self-report measure of depressive symptomatology
14). A score of 10 or more is considered indicative of
linically significant levels of depressive symptoms (15).
lthough the BDI is not used to diagnose clinical depres-
ion, it is a well-validated instrument for assessing the
everity of depressive symptoms. Moreover, elevated symp-
oms of depression measured by the BDI are associated with
n increased risk of adverse events in cardiac patients,
ncluding patients with HF (3,7,16,17). These studies also
ocument that the cut point of a BDI score of 10 or more
s applicable in cardiac patient populations, where it has
een associated with poorer prognosis (3,16,17).
-year follow-up assessments. On the 1-year anniversary
2 weeks) of participants’ baseline assessments, 147 sur-
iving participants repeated the BDI to reassess their
epression symptoms. Medical records also were examined
o document current health status, hospitalizations during
he past year, and antidepressant medication use.
ong-term follow-up of vital status and hospitalizations.
articipants’ medical records were reviewed on a yearly
asis, over a median of 5 consecutive years from baseline
with a range of 4 to 7 years and no losses to follow-up) on
he anniversary of their baseline assessments by trained
esearch assistants blinded to patients’ depression status.
atients also were contacted annually by mail and asked to
ndicate whether they had been hospitalized during the past
ear and provided consent for retrieval of their hospitaliza-
Abbreviations
and Acronyms
BDI  Beck Depression
Inventory
CHD  coronary heart
disease
CI  confidence interval
HF  heart failure
HR  hazard ratio
ICD  implantable
cardioverter-defibrillator
LVEF  left ventricular
ejection fraction
MI  myocardial infarction
NT-proBNP  plasma
N-terminal pro–B-type
natriuretic peptideion records. The primary end point was defined as the time
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Depression and Heart Failure January 25, 2011:418–23o cardiovascular hospitalization or death (whichever oc-
urred first) within the follow-up period. Patient mortality
as verified through hospital and emergency medical ser-
ices records. Cardiovascular hospitalizations included hos-
italizations for MI, stroke, treatment for worsening heart
ailure, cardiac surgery including coronary artery bypass
rafts, and heart transplantation. To develop a fuller under-
tanding of the relationship of depression and clinical
utcomes, we also considered all-cause hospitalization or
ortality as a secondary composite end point.
tatistical methods. Cox proportional hazards regression
odels were used to examine the relationship between
aseline characteristics and events (death and hospitaliza-
ions) during the median 5-year follow-up (with range of 4
o 7 years and no losses to follow-up). Age, HF cause,
T-proBNP level, LVEF, baseline BDI score, 1-year
hange in BDI score (BDI score at 1 year minus baseline
DI score), and antidepressant medication use had planned
nclusion in the primary model. Hospitalizations occurring
uring the first year were used as an indicator of medical
tatus for that year and also were included in the planned
rimary proportional hazards regression model to address
he possibility that clinical events during the first year of
ollow-up could drive changes in depression symptoms
uring the interval between baseline and the reassessment 1
ear later. To minimize the possible influence of clinical
vents during the first year on subsequent 1-year BDI
cores, outcomes were considered as clinical events occur-
ing at least 1 year after initial baseline assessments. Thus,
utcomes were defined as death or hospitalizations occur-
ing only after the first year of follow-up data had been
ollected (including 1-year BDI score) for each participant.
econdary sensitivity analyses for the evaluation of robust-
ess of findings from the planned model allowed other
otential explanatory factors (including New York Heart
ssociation functional class; diabetes, hypertension; hyper-
holesterolemia; myocardial infarction; tobacco use; glomer-
lar filtration rate [modified Cockcroft-Gault equation];
mplantable defibrillator; and treatment with a beta-blocker,
iuretic, angiotensin converting enzyme inhibitor, nitrate,
arfarin, or statin) to be available for entry into the planned
odel by stepwise selection (significance level entry/exit 
.1). For Cox regression analyses, baseline NT-proBNP and
DI scores were trimmed at the ninety-fifth percentiles to
revent excessive influence of outliers; NT-proBNP was
xpressed as NT-proBNP/1,000 and age was expressed as
ge/10. Descriptive statistics were means with standard
eviations for continuous variables and counts with percent-
ges for categorical variables. Also, Student t tests and
hi-square tests were used for the comparison of character-
stics of study participants who died before or were other-
ise unavailable for reassessment of depressive symptoms,
ith those comprising the study sample (n 147) evaluated
sing the Cox regression analyses. mesults
aseline characteristics. Demographic and clinical char-
cteristics of the study sample are shown in Table 1. The
ean age at baseline was 57 years, with a range of 27 to 88
ears. Most patients were male (70%), and approximately
alf were minorities. Most patients had New York Heart
ssociation functional class II (59%) or class III (37%)
evels, and most patients were taking a beta-blocker (88%)
r an angiotensin converting enzyme inhibitor (86%).
wenty percent of patients were taking antidepressant
aseline Characteristicsor the Study Sample (n  147)Table 1 B selin Characteristicsfor the Study Sample (n  147)
Demographic and history
Age (yrs) 57 13
Female 30
Minority ethnicity 51
BMI (kg/m2) 31.4 6.9
Ischemic cause 45
NYHA functional class
I 3
II 59
III 37
IV 1
Implantable defibrillator 11
Pacemaker 10
SBP (mm Hg) 99 17
DBP (mm Hg) 60 10
HR (beats/min) 66 11
Current smoker 19
Time since HF diagnosis (yrs) 4.8 4.2
Baseline assessments
Left ventricular ejection fraction 32 11
NT-proBNP (pg/ml) 1,159 1,466
Medications at baseline
Antidepressants 20
Beta-blockers 88
ACE inhibitors 86
ARBs 7
Nitrates 31
Warfarin 26
Statins 46
Aspirin 55
Diuretics 93
Laboratory values at baseline
Total cholesterol (mg/dl) 192 51
Sodium (mEq/l) 140 3
Hemoglobin (g/dl) 13.4 1.5
Creatinine (mg/dl) 1.3 0.6
BUN (mg/dl) 25.1 16.3
Medical comorbidities
Diabetes 41
Hypercholesterolemia 48
ata are presented as mean  SD or %.
ACE  angiotensin converting enzyme; ARB  angiotensin receptor blocker; BMI  body mass
ndex; BUN blood urea nitrogen; DSB diastolic blood pressure; HF heart failure; HR hazard
atio; NT-proBNP  plasma N-terminal pro–B-type natriuretic peptide; NYHA  New York Heart
ssociation; SBP  systolic blood pressure.edication (selective serotonin reuptake inhibitors, tricyclic
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January 25, 2011:418–23 Depression and Heart Failurer tetracyclic agents, and monoamine-oxidase inhibitors)
t baseline, and the average BDI score at baseline was
0 (SD: 6, range: 0 to 37). The study sample consisted of
47 patients, which represents 83% of the 177 patients who
urvived 1 year after baseline assessments from our original
tudy (3). Compared with the survivors, patients who died
uring the first year of follow-up (n  27) had, at baseline,
igher resting heart rates (p  0.021), lower LVEFs (p 
.028), higher NT-proBNP levels (p  0.0001), and were
ess likely to be taking nitrates (p 0.041). Cox proportional-
azards regression analyses revealed that only NT-proBNP
nd LVEF were related to death (all p  0.01) within the
rst year after baseline assessments. There were few differ-
nces in any of the demographic or clinical characteristics of
he 30 patients who survived at least 1 year, but who were
navailable for follow-up compared with the remaining 147
atients, with the exceptions of their having higher baseline
ystolic blood pressure (p  0.011), higher NT-proBNP
evels (p  0.021), lower hemoglobin levels (p  0.015),
nd being more likely to be diabetic (p  0.024). It is of
ote that there were no differences in baseline BDI score
etween the present study sample (n  147) and those 30
atients who were unavailable for 1-year follow-up (10.2 
.9 vs. 10.9  6.4, respectively, p  0.579).
he relationship of depression to cardiovascular hospitaliza-
ions and mortality. The median follow-up period from
aseline was 5 years, with a range of 4 to 7 years; no patients
ere lost to follow-up. Of the 147 patients who survived at
east 1 year and completed a second BDI assessment, 127
86%) either died or were hospitalized at least once, includ-
ng 112 (76%) such events the result of cardiovascular events
uring the subsequent follow-up period (with a median of 4
ears). During the follow-up period, 53 (36%) of the 147
articipants died, of which 40 deaths were the result of
ardiac causes; 15 of these 53 deaths occurred before any
ospitalizations during the follow-up period. The planned
ultivariate Cox proportional-hazards regression analysis
evealed that ischemic cause (hazard ratio [HR]: 1.83, 95%
onfidence interval [CI]: 1.22 to 2.75, p  0.004), NT-
roBNP (1,000 pg/ml HR: 1.17, 95% CI: 1.01 to 1.36, p
ultivariate Cox Proportional Hazards Models Assessing the AssocBeck Depression Inven ory Score) and 1-Y ar Change in D pressiocore) Wi h mposite End Points of Hospit lization a d Death
Table 2
Multivariate Cox Proportional Hazards Models Assessi
(Beck Depression Inventory Score) and 1-Year Change
Score) With Composite End Points of Hospitalizations
Planned Model Characteristic
Cardiac Hosp
(11
p Value
Age (yrs/10) 0.103
Cause (1  ischemic; 0  nonischemic) 0.004
NT-proBNP (pg/ml/1,000) 0.031
LVEF (%) 0.011
Baseline depression symptoms (BDI score) 0.001
1-year change in BDI score 0.007
Antidepressant (1  yes; 0  no) 0.092
Hospitalization in first year (1  yes; 0  no) 0.001DI  Beck Depression Inventory; CI  confidence interval; HR  hazard ratio; LVEF  left ventricular ej.03), LVEF (HR: 0.97, 95% CI: 0.95 to 0.99, p  0.011),
nd hospitalization within the first year after baseline
ssessments (HR: 2.4, 95% CI: 1.57 to 3.66, p  0.001)
ere associated with cardiovascular hospitalization or mor-
ality (Table 2). In this same model, the extent of baseline
epression symptoms also was strongly related to risk for
ardiovascular hospitalization or mortality (1-point BDI
R: 1.1, 95% CI: 1.06 to 1.14, p  0.001), and so was
hange in BDI score at 1 year (1-point BDI change HR:
.07, 95% CI: 1.02 to 1.12, p  0.007). In secondary
nalyses, of the variables eligible for contributing further to
he planned model through stepwise selection, current
moking status (HR: 1.92, 95% CI: 1.14 to 3.23, p 0.014)
nd presence of an implantable defibrillator (HR: 0.51, 95%
I: 0.28 to 0.92, p  0.024) were added to the model.
owever, the addition of these factors did not influentially
lter the results for the explanatory values of the variables in
he original model, including baseline depression symptoms
nd 1-year change in depression symptoms, confirming that
he original planned model was robust for its results.
The change in BDI score from baseline to 1-year
ollow-up ranged from a 14-point reduction to an increase
f 19 points. To provide a better understanding of how
hanges in depressive symptoms were related to change in
isk of adverse clinical outcomes, we created 3 descriptive
ategories. Ideally, each of the categories would have ap-
roximately one third of the participants, and 25% at a
inimum; moreover, one would like the middle category for
variable that is reflective of change to represent little or no
hange. Sixty-five participants (44%) showed a 2-point
hange or less in either direction in BDI score from baseline
o the 1-year follow-up, whereas 29% showed either an
ncrease in BDI of 3 points or more (n  43), and 27%
howed a decrease of at least 3 points (n  39). In
xploratory analyses, these BDI-change categories were
ntered into our planned regression model in place of the
aw BDI-change score to assess the nature of changing BDI
ffects on outcomes. Compared with patients showing
inimal (2-point) change in BDI, those exhibiting a
-point increase or more, indicating worsening depression
n of Baseline Depression Symptomsmptom (Change in Beck Depression Inventorye Association of Baseline Depression Symptoms
epression Symptoms (Change in Beck Depression Inventory
eath
tion or Death
ts)
All-Cause Hospitalization or Death
(127 Events)
HR (95% CI) p Value HR (95% CI)
1.17 (0.97–1.41) 0.019 1.25 (1.04–1.51)
1.83 (1.22–2.75) 0.053 1.46 (0.99–2.14)
1.17 (1.01–1.36) 0.129 1.12 (0.97–1.29)
0.97 (0.95–0.99) 0.098 0.98 (0.96–1.00)
1.10 (1.06–1.14) 0.001 1.09 (1.05–1.13)
1.07 (1.02–1.12) 0.023 1.06 (1.01–1.11)
0.63 (0.36–1.08) 0.309 0.78 (0.48–1.26)
2.40 (1.57–3.66) 0.001 2.36 (1.59–3.51)iation Syng th
in D
and D
italiza
2 Evenection fraction; other abbreviation as in Table 1.
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Depression and Heart Failure January 25, 2011:418–23ymptoms, were at more than twice the risk of adverse
utcomes (HR: 2.12, 95% CI: 1.31 to 3.43, p  0.002);
owever, patients whose BDI scores were 3 points or more
ower at the 1-year follow-up were at a relatively similar risk
ompared with those exhibiting a minimal BDI change
HR: 0.87, 95% CI: 0.5 to 1.48, p  0.59).
he relationship of depression to all-cause hospitalizations
nd mortality. In our planned model, age (10-year HR:
.25, 95% CI: 1.04 to 1.51, p  0.019) and hospitalization
ithin the first year after baseline assessments (HR: 2.36,
5% CI: 1.59 to 3.51, p  0.001) were associated with
ll-cause hospitalization or mortality over the subsequent
ollow-up period (Table 2). The extent of baseline depres-
ion symptoms also was related to increased risk for all-
ause hospitalizations or mortality (1-point BDI HR: 1.09,
5% CI: 1.05 to 1.13, p  0.001), and so was change in
DI score at 1 year (1-point BDI change HR: 1.06, 95%
I: 1.01 to 1.11, p  0.023). Secondary analyses showed
hat no additional variables were added to the planned
odel through stepwise selection, confirming that the
lanned model was robust.
In exploratory regression analyses, we substituted our
ategorical variables indicating worsening, improving, or
inimal change in BDI score for the continuous measure of
-year change in BDI score. For all-cause hospitalizations,
here was a trend for increased risk associated with worsening
epression symptoms compared with minimal or no change in
epression symptoms (HR: 1.48, 95% CI: 0.96 to 2.29,
 0.077), whereas improving depression symptoms were not
ssociated with altered risk compared with minimal or no
hange (HR: 0.78, 95% CI: 0.47 to 1.28, p  0.32).
iscussion
he present findings confirm and extend our previous
bservations by showing that symptoms of depression are
ssociated with adverse clinical outcomes, including cardio-
ascular (or all-cause) hospitalization and death, over a
edian of 5 years of follow-up from baseline (with range of
to 7 years and no losses to follow-up), even after
ontrolling for the severity of HF disease and other estab-
ished risk factors, and that worsening of depression addi-
ionally was associated with such adverse events compared
ith patients whose depressive symptoms remained rela-
ively stable over the initial 1-year follow-up period. To our
nowledge, this is the first study to evaluate prospectively
he clinical impact of changing depression symptoms in HF
atients, and our observations demonstrate that such
hanges do indeed affect clinical outcomes. Specifically, a
-point change in BDI score was associated with a 7%
lteration in risk (per unit of time) for cardiovascular
ospitalizations and mortality. Importantly, the effects of
hange in depression symptoms were independent of base-
ine depression symptoms and HF disease severity bio-
arkers, as well as hospitalizations occurring during the
ear over which depression symptoms were monitored. ixploratory analyses designed to understand better the
atter finding suggest that worsening symptoms of depres-
ion in HF patients may be of particular concern; an
ncrease in depressive symptoms of 3 points or more in BDI
core over a 1-year follow-up period was associated with a
ore than 2-fold increased risk of cardiovascular hospital-
zation or death compared with minimal change (2 BDI
oints). Our findings are consistent with observations in MI
atients, in whom worsening symptoms of depression have
een associated with greater risk of subsequent mortality
9–11).
Our study found no association between antidepressant
se and clinical outcomes. However, because the study was
ot designed to assess the impact of antidepressant treat-
ent on outcomes, the significance of this observation is
nclear. There are currently no published data from ran-
omized clinical trials of HF patients indicating whether
nterventions designed to modify depression symptoms may
lter long-term clinical outcomes. Although the SADHART
Sertraline Against Depression and Heart Disease in Chronic
eart Failure) trial (18) was designed to be a safety and efficacy
rial and was not powered to evaluate adverse clinical outcomes,
he incidence of cardiovascular events in a subgroup of more
everely depressed patients with acute coronary syndromes
andomized to sertraline treatment was 14.5%, compared with
2.4% among those receiving a placebo. In the Enhancing
ecovery in Coronary Heart Disease trial, the rates of nonfatal
I and all-cause mortality were similar between post-MI
atients randomized to cognitive behavior therapy and educa-
ion controls (19), although a post hoc analysis revealed that
atients who received antidepressant medication had improved
urvival compared with similar patients not receiving antide-
ressants (20). Moreover, patients randomized to the cognitive
ehavior therapy condition who exhibited an increase in
epressive symptoms had higher event rates compared with
hose patients who showed an improvement in depressive
ymptoms (9). In a recently completed randomized clinical trial
n HF patients with depression (21), no antidepressant benefit
f sertraline compared with placebo was observed, although
emitting depression symptoms were found to be associated
ith improved health status and quality of life (22).
tudy limitations. It is important to note that the obser-
ational data reported in the present study do not lend
hemselves to causal inferences, nor to insights into the
otential effects of interventions designed to modify symp-
oms of depression. Other limitations of the present study
nclude absence of changes in depression during the
ollow-up period. However, changes in depression symp-
oms during the follow-up period would be difficult to
nterpret because such changes would be concomitant with
hanging HF disease severity. The reported analyses evalu-
te the role of change in depressive symptoms before the
nset of the follow-up period and therefore are explanatory.
he sample size of the present study also was relatively
mall, but a significant relationship between 1-year change
n depression symptoms and subsequent clinical outcomes
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January 25, 2011:418–23 Depression and Heart Failureas observed despite this limitation. It also should be noted
hat the HF disease severity biomarkers (NT-proBNP and
VEF) were assessed only at baseline, not at the time of the
eassessment of depressive symptoms 1 year later; however,
ur inclusion of hospitalizations during that 1-year period
as designed to minimize this potential limitation.
onclusions
n summary, elevated depression symptoms and worsening
epression symptoms were found to be explanatory risk
actors for adverse clinical outcomes in HF patients, inde-
endent of HF disease severity. Our findings support the
ecent American Heart Association’s position encouraging
epression screening (23) and further suggest that it may be
rudent for clinicians to reassess symptoms of depression
outinely in HF patients to determine better appropriate
edical management of these patients who are at increased
isk for adverse clinical outcomes and impaired quality of
ife.
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ox 3119, Duke University Medical Center, Durham, North
arolina 27710. E-mail: sherw002@mc.duke.edu.
EFERENCES
1. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart Disease and
Stroke Statistics 2009 Update: a report from the American Heart
Association Statistics Committee and Stroke Statistics Subcommittee.
Circulation 2009;119:e21–181.
2. Guck TP, Elsasser GN, Kavan MG, Barone EJ. Depression and
congestive heart failure. Congestive Heart Failure 2003;9:163–9.
3. Sherwood A, Blumenthal JA, Trivedi R, et al. Relationship of
depression to death or hospitalization in patients with heart failure.
Arch Intern Med 2007;167:367–73.
4. Jiang W, Alexander J, Christopher E, et al. Relationship of depression
to increased risk of mortality and rehospitalization in patients with
congestive heart failure. Arch Intern Med 2001;161:1849–56.
5. Vaccarino V, Kasl SV, Abramson J, Krumholz HM. Depressive
symptoms and risk of functional decline and death in patients with
heart failure. J Am Coll Cardiol 2001;38:199–205.
6. Murberg TA, Furze G. Depressive symptoms and mortality in patients
with congestive heart failure: a six-year follow-up study. Med Sci
Monitor 2004;10:CR643–8.
7. O’Connor CM, Jiang W, Kuchibhatla M, et al. Antidepressant use,
depression, and survival in patients with heart failure. Arch Intern
Med 2008;168:2232–7. K8. Pelle AJ, Gidron YY, Szabo BM, Denollet J. Psychological predic-
tors of prognosis in chronic heart failure. J Cardiac Failure
2008;14:341–50.
9. Carney RM, Blumenthal JA, Freedland KE, et al. Depression and late
mortality after myocardial infarction in the Enhancing Recovery in
Coronary Heart Disease (ENRICHD) study. Psychosom Med 2004;
66:466–74.
0. Lesprance F, Frasure-Smith N, Talajic M, Bourassa MG. Five-year
risk of cardiac mortality in relation to initial severity and one-year
changes in depression after myocardial infarction. Circulation 2002;
105:1049–53.
1. Wassertheil-Smoller S, Applegate WB, Berge K, et al. Change in
depression as a precursor of cardiovascular events. Arch Intern Med
1996;156:553–61.
2. Havranek EP, Spertus JA, Masoudi FA, Jones PG, Rumsfeld JS.
Predictors of the onset of depressive symptoms in patients with heart
failure. J Am Coll Cardiol 2004;44:2333–8.
3. Koenig HG. Depression outcome in inpatients with congestive heart
failure. Arch Intern Med 2006;166:991–6.
4. Beck AT, Beamesderfer A. Assessment of depression: the depression
inventory. Mod Probl Pharmacopsychiatry 1974;7:151–69.
5. Beck AT, Steer RA. Beck Depression Inventory manual. San Antonio,
TX: The Psychological Corporation, Harcourt-Brace-Jovanovich,
1987.
6. Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month
prognosis after myocardial infarction. Circulation 1995;91:999–1005.
7. Carney RM, Blumenthal JA, Catellier D, et al. Depression as a risk
factor for mortality after acute myocardial infarction. Am J Cardiol
2003;92:1277–81.
8. Glassman AH, O’Connor CM, Califf RM, et al. Sertraline treatment
of major depression in patients with acute MI or unstable angina.
JAMA 2002;288:701–9.
9. Berkman LF, Blumenthal J, Burg M, et al. Effects of treating
depression and low perceived social support on clinical events after
myocardial infarction: the Enhancing Recovery in Coronary Heart
Disease Patients (ENRICHD) Randomized Trial. JAMA 2003;289:
3106–16.
0. Taylor CB, Youngblood ME, Catellier D, et al. Effects of antidepres-
sant medication on morbidity and mortality in depressed patients after
myocardial infarction. Arch Gen Psychiatry 2005;62:792–8.
1. Jiang W, O’Connor C, Silva SG, et al. Safety and Efficacy of
Sertraline for Depression in Patients with CHF (SADHART-
CHF): a randomized, double-blind, placebo-controlled trial of
sertraline for major depression with congestive heart failure. Am
Heart J 2008;156:437– 44.
2. Fiuzat M, Jiang W, Spertus J, et al. Effects of successful depression
intervention on health status in patients with chronic heart failure and
major depressive disorder: findings from the SADHART-CHF Ran-
domized Controlled Trial. J Cardiac Failure 2009;15:S86.
3. Lichtman JH, Bigger JT, Blumenthal JA, et al. Depression and
coronary heart disease: recommendations for screening, referral, and
treatment. A science advisory from the American Heart Association
Prevention Committee of the Council on Cardiovascular Nursing,
Council on Clinical Cardiology, Council on Epidemiology and Pre-
vention, and Interdisciplinary Council on Quality of Care and Out-
comes Research. Circulation 2008;118:1768–75.ey Words: depression y heart failure.
